Neos Kicks Off Global Indie Game Publishing Business
25.3.2025 15:00:00 CET | Business Wire | Press release
-New Label "IndieTech Games" Launched-
Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/
IndieTechGames
Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units.
The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units.
Through the sales and marketing of our in-house developed titles, we have had more opportunities to engage with games from around the world. At the same time, we have also increasingly encountered indie games that, for various reasons, have not been distributed globally.
In response, Neos has launched a new label, "IndieTech Games," to bring high-quality indie games—those that developers or rights holders are unable to publish themselves—to gamers worldwide. Leveraging our experience in game planning, development, and marketing, we will discover and showcase unique and captivating indie titles, distributing them globally in collaboration with our network of regional partners.
At "IndieTech Games," we carefully select titles that, like Neos' in-house developed games, place great importance on characters, art, and storytelling. Our goal is to create a publishing label that developers feel truly glad to work with.
At launch, we plan to release the following three titles. Details on pricing and release dates will be announced separately.
Title: PIGROMANCE
Genre: Action Puzzle
Developer/Licensor: GRAVITY (Korea)
Platform: Nintendo Switch
Rating: CERO C
Territory: Worldwide
Languages: Japanese, English, Korean, French, German, Spanish, Portuguese, Simplified Chinese, Traditional Chinese
Title: SEDAP! A Culinary Adventure
Genre: Action Adventure
Developer/Licensor: kopiforge (Singapore)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Taiwan, Hong Kong, Southeast Asia
Languages: Japanese, English, Korean, Indonesian, Filipino, Malay, Simplified Chinese, Traditional Chinese
Title: Sunsethills
Genre: Puzzle Adventure
Developer: Cotton Game (China)
Licensor: Asmik Ace (Japan)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Southeast Asia
Languages: Japanese, English, Korean, Simplified Chinese, Traditional Chinese
- Official X: https://x.com/indietech_games
- Official Instagram: https://www.instagram.com/indietech_games/
- Official Facebook: https://www.facebook.com/profile.php?id=61574205204129
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320035646/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom